In such cases, neurons have been found within particular layers that either elicit a movement that persists beyond their initial activation, or must be continually activated to continue the movement.
We describe how the antennal grooming circuit and other well-described circuits are organized such that some neurons induce movements that persist beyond their initial activation, whereas other neurons must be continually activated to continue the movement.
During their endosomal passage the activated receptors will continue to activate cytoplasmic signaling cascades, mainly by the help of endosomal scaffold proteins.
Studies of cells expressing SGK1-K127A or CD2-P110α-R1130P showed that glucocorticoids continue to activate the α-ENaC promoter even if the activation of endogenous SGK1 is prevented and so, although SGK1 augments the transcriptional response to dexamethasone (see above), increased SGK1 activity does not seem to be necessary for the hormonal activation of the α-ENaC gene promoter.
The specificity of PGRP-SB1 enzymatic activity could contribute to the elimination of bacteria by degrading their cell wall, while allowing TCT to accumulate and continue to activate the other branches of the immune response.
Since CD8+ T-cells from patients with perforin-associated FHL fail to kill infected cells, these killer cells continue to activate macrophages and to deliver proliferation signals to T-cells.
These residual androgens are still in the range expected to continue to activate the receptor, albeit significantly lower than those in tumors which were not treated with estradiol.
This is in line with the use of additional and or alternate molecules which can continue to activate β-catenin signaling 9– 11.
Sargent et al. [ 19] reported that m-chlorophenyl piperazine (m-CPP), a 5HT2C receptor agonist, may continue to activate brain 5-HT2C receptors and this effect is associated with decreases in appetite and body weight.
This study addresses a critical limitation of GDEPT, namely, that tumor cells transduced with a prodrug-activating enzyme, when treated with a prodrug, become exposed to high local concentrations of the active drug metabolite and as a consequence die rapidly, thereby halting their ability to continue to activate the prodrug substrate and generate tumor cell toxic drug metabolites.
